Emerging evidence indicates that the gut microbiome modulates opioid-related behaviors through bidirectional communication with mesolimbic reward circuitry. Preclinical studies show that antibiotic-induced microbiome depletion, germ-free conditions, and developmental microbial disruption alter opioid reward and reinforcement in animal models. Rather than uniformly increasing or decreasing opioid responsivity, microbiome disruption produces paradigm-specific and stage-dependent effects across distinct components of reinforcement learning. Reduced microbial diversity is associated with decreased production of short-chain fatty acids (SCFAs), altered gut barrier integrity, and enhanced peripheral immune signaling. These changes converge on the ventral tegmental area (VTA) and nucleus accumbens (NAc), modifying dopaminergic transmission and transcriptional plasticity within reward-related circuits. Notably, microbiome depletion reduces morphine conditioned place preference, whereas, in separate paradigms, it increases fentanyl self-administration and motivational responding under progressive ratio schedules, revealing a dissociation between hedonic reward and reinforcement processes. SCFA supplementation can partially rescue reward-related phenotypes, supporting a mechanistic role for microbial metabolites. Across reinforcement paradigms, microbiome status emerges as a dynamic regulator of opioid reinforcement rather than a simple modulator of reward magnitude. Importantly, antibiotic exposure, which is common during infectious disease treatment of individuals with opioid use disorder (OUD), may represent a clinically relevant and underappreciated modifier of reinforcement sensitivity and relapse risk. This review uniquely integrates microbiome disruption, stress sensitivity, negative affect, and neuroimmune priming during protracted abstinence to highlight antibiotic exposure as an overlooked but actionable factor in OUD recovery.
Aburahma et al. (2026) studied this question.